
Pasirinkite etiketę
rodoma tiesiai ant flakonoReta + Tesamorelin Blend
GLP-1
- Siunčiame iš Vokietijos
Užsakymas
- DHL su sekimu
- Diskreti pakuotė
Trumpai
Reta + Tesamorelin Blend skaičiais
Pagrindiniai rodikliai iš mūsų žinyno.
Visas žinyno įrašas- Type
- Injectable blendtriple agonist + GHRH analog
- Sizes
- 20 mg1 size in the shop
What studies show
All 4 sources in the lexiconRetatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)
New England Journal of Medicine (PubMed PMID 37366315)Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)
Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)
J Acquir Immune Defic Syndr (PubMed PMID 20101189)
Atsiliepimai
Ką sako klientai
Tik tikri užsakymai, kuriuose buvo Reta + Tesamorelin Blend.
Visi atsiliepimaiProduktui Reta + Tesamorelin Blend laboratorinės analizės dar nėra. Balsuoti už taiUžsakykite tyrimą, mes apmokame pusęVisos laboratorinės analizės
Žinios
Viskas apie Reta + Tesamorelin Blend
Išsami informacija netrukus.
Dozavimas
Įkeliama dozavimo informacija …
Pravers
Ko dar jums reikės
Bakteriostatinis vanduo į krepšelį pridedamas automatiškai. Švirkštai ir servetėlės - vienu paspaudimu.
Insulino švirkštai
10 vnt. · 5.50 €
Spiritinės servetėlės
50 vnt. · 10 €
Kiek vandens?
Vienetai ant švirkšto jūsų flakono dydžiui.
Atidaryti skaičiuoklę →Is the Reta + Tesamorelin Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.
What is the catch with the fixed mix?
The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.
What do the Retatrutide trials show?
In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.
What do the tesamorelin trials show?
In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.
Which side effects were seen with the components?
Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.
Susiję
Susiję produktai
Tirzepatide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
Dydžių: 10
Patikrinta laboratorijoje
= nuo 10 €/flakonas
Retatrutide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
Dydžių: 11
Patikrinta laboratorijoje
= nuo 16 €/flakonas
Semaglutide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
Dydžių: 6
Patikrinta laboratorijoje
= nuo 10 €/flakonas
Mazdutide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
Dydžių: 2
= nuo 32 €/flakonas
Reta + Tesamorelin Blend